Stay updated on Pembrolizumab + Idelalisib in Lung Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab + Idelalisib in Lung Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab + Idelalisib in Lung Cancer Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:38:24.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a potential update or modification in the study details related to the combination of pembrolizumab and idelalisib in NSCLC patients for increased response rates.
    Difference
    0.1%
    Check dated 2024-06-06T14:31:06.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria,' providing examples such as general health condition or prior treatments. Additionally, the 'Eligibility Criteria Description' now specifies that subjects must have documented metastatic or recurrent NSCLC from biopsy and must have failed or progressed on platinum-based chemotherapy.
    Difference
    24%
    Check dated 2024-05-22T21:11:15.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:28:09.000Z thumbnail image

Stay in the know with updates to Pembrolizumab + Idelalisib in Lung Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Idelalisib in Lung Cancer Clinical Trial page.